This site is intended for healthcare professionals

FDA accepts Omblastys for priority review in pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.- Y-mAbs Therapeutics

Read time: 1 mins
Published:1st Jun 2022

Y-mAbs Therapeutics announced that the Biologics License Application for Omblastys (omburtamab) for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma has been accepted for priority review by the FDA.

The FDA set an action date of November 30, 2022, under the Prescription Drug User Fee Act. The Agency also indicated in the BLA filing communication letter that it is planning to hold an advisory committee meeting in October 2022 to discuss the application.

Condition: Neuroblastoma
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.